Mustang Bio Q1 net loss widens to $955,000; operating loss increases to $1.06 million

• Mustang Bio posted a net loss of USD 955,000, widening from USD 153,000 a year earlier as operating loss expanded to USD 1.06 million.
• Total operating expenses climbed more than tripled to USD 1.06 million, led by research and development swinging to expense of USD 178,000 from a benefit of USD 964,000.
• General and administrative costs fell 28% to USD 880,000, while interest income, net edged up to USD 103,000.
• Cash and cash equivalents totaled USD 16.3 million at March 31, 2026, with operating cash outflow narrowing to USD 1.01 million.
• Mustang Bio said it is exploring an investigator-sponsored single-institution MB-109 trial at City of Hope that could start in the third quarter of 2026 following termination of its Worcester, Mass. cell processing center lease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-055598), on May 05, 2026, and is solely responsible for the information contained therein.